Week 11 Diabetes Flashcards
(210 cards)
1
Q
What are normal blood glucose levels?
A
80-90mg/100ml
4-6 mmol.
2
Q
What is the major endocrine organ responsible for glucose homeostasis?
A
Pancreas (Islets of Langerhans)
3
Q
What two hormones does the pancreas produce and what is their function?
A
Insulin: promotes glucose uptake form the blood and storage in tissues.
Glucagon: promotes glucose metabolism from tissues to increase blood glucose levels.
4
Q
What are the clinical manifestations of hypoglycemia?
A
Early:
Palpitations
Tachycardia
Diaphoresis
Anxiety
Weakness, hunger, nausea
Prolonged:
Hypothermia
Confusion, hallucinations, seizures
Coma
5
Q
What are the clinical manifestations of hyperglycemia?
A
Early:
Polydipsia
Polyuria
Altered vision
Weight loss, mild dehydration
Prolonged:
Cardiac arrythmias
Coma
6
Q
How much of the pancreas is exocrine?/endocrine?
A
Exocrine: 97-99 by weight%
Endocrine: 1-3 by weight%
7
Q
What are the Islet endocrine cell types?
A
a-cells (15-20%): secrete glucagon.
B-cell (65-80%): secrete insulin and Islet Amyloid PolyPeptide (IAPP/amylin)
d-cell (3-10%): secrete somatostatin
PP cell (3-5%): secrete pancreatic polypeptide
The amounts of each cell type varies from person to person.
8
Q
What is the function of IAPP/amylin?
A
Decreases gastric emptying, suppresses glucagon secretion, stimulates satiety center.
Controls blood gluces in an insulin sparing fashion.
9
Q
What is the function of pancreatic polypeptide (PP)?
A
Delays gastric emptying and reduces acute food intake.
Reduces appetite and food intake.
10
Q
Discuss Islet blood flow
A
Rich vascular supply to Islets.
B, a, and d cells are aligned along blood vessels.
This allows communication for constant blood glucose regulation. “Very good neighbourhood to be in”
11
Q
Discuss Islet innervation
A
Richly innervated by ANS.
PNS: Vagus nerve (CNX), Ach stimulates insulin secretion.
SNS: Post-ganglionic fibers originate in celiac ganglion. Norepi inhibits insulin secretion. Epi also plays a part.
12
Q
Discuss proinsulin synthesis
A
A&B chains and a C peptide
Synthesized in the RER, transits through GA, packaged into secretory vesicles and can be stored in granules for hours or days.
In the mature secretory granule insulin forms a dense crystal with zinc in center, C-peptide in granule halo.
Glucose stimulates proinsulin synthesis.
13
Q
Discuss proinsulin processing
A
Processed in granules by prohormone convertase enzymes PC1/3 and PC2.
Cleavage by PC1/3 and PC2 followed by removal of basic residues by carboxypeptidase E.
This results in equimolar amounts of Insulin and C-peptide.
C-peptide has no established biological action and is excreted in urine. Can be used to assess a person’s insulin secretory capability.
Proinsulin cleavage is efficient, only 2-5% of total insulin is secreted as proinsulin in normal folks.
14
Q
What is the major stimulus for insulin secretion?
A
Glucose.
GLUCOSE-DEPENDENT: protects against inappropriate secretion of insulin.
15
Q
Discuss neural regulation of insulin secretion
A
PNS: Vagus nerve, Ach: Simulates islets
SNS: Norepi/epi: Inhibit islets
GLUCOSE-DEPENDENT
16
Q
Discuss hormonal regulation of insulin secretion
A
STIMULATORY HORMONES:
Incretins (GIP, GLP-1) enhance glucose stimulated insulin secretion.
Released in intestines after a meal.
GLP-1 suppresses glucagon release, delays gastric emptying, inhibits food intake
INHIBITORY HORMONES:
Somatostatin from gut inhibits adenylyl cyclase and PKA: inhibits both insulin and glucagon secretion.
GLUCOSE-DEPENDENT
17
Q
What other nutrients play a stimulatory role other than glucose?
A
Arg, Lys: potentiate the GLUCOSE stimulus for insulin secretion.
GLUCOSE-DEPENDENT
18
Q
List the stimulatory and inhibitory mechanisms of insulin secretion.
A
STIMULATORY:
GIP, GLP-1 (incretins)
Glucagon - yes glucagon (thats all you need to know right now)
Ach (PNS CN X)
Glucose
Arg, Lys
Free fatty acid exposure
INHIBITORY:
Somatostatin (Gut and d-cells)
Norepi/epi (SNS post ganglionic fibers from celiac ganglion)
19
Q
What does prolonged exposure to glucose or free fatty acids lead to?
A
Glucotoxicity and lipotoxicity
Apoptosis of B-cells
20
Q
Discuss the simplified mechanism of glucose-induced insulin secretion
A
- Glucose enters B-cell via GLUT-2 transporter.
- Glucokinase phosphorylates Glucose to G6P.
- Glycolysis produces ATP.
- ATP sensitive K channels (with sulfonylurea receptors) close.
- B-cell depolarizes.
- Voltage gated Ca channels open and Ca enters cell.
- Exocytosis of insulin secretory granules.
21
Q
What is the rate limiting step of glucose induced insulin secretion?
A
Glucokinase phosporylation.
Considered the GLUCOSE SENSOR of the B-cell.
22
Q
What is the general mechanism of sulfonylurea treatment?
A
Sulfonylurea receptor is part of ATP sensitive K channels.
Binding of sulfonylureas could lead to closure of K channel and stimulate insulin secretion by a glucose-INdependent mechanism.
23
Q
What are the major target tissues of insulin?
A
Muscle
Fat
Liver
**Promotes energy storage = Anabolic
24
Q
What effects does insulin have on carbohydrate metabolism?
A
Overall: increased glucose storage and utilization
Myocytes & adipocytes:
Stimulates glucose uptake by upregulating GLUT4 on cell surface.
In mm glucose is used as energy or stored as glycogen.
In fat glucose is stored at G3P+FFAs = triglycerides.
Liver:
Activation of glycogen synthase = increased glucose storage.
Activation of glucokinase, phosphofructokinase and pyruvateK = increased glucose utilization.
Inhibits glycogenolysis via inactivation of liver glycogen phosphorylase.
Inhibits gluconeogenesis via inhibition of pyruvate carboxylase, PEPCK and fructose 1,6 diphsphatase.
25
What effects does insulin have on fat metabolism?
Overall: Increased fat storage in adipose tissue.
Increased FA and Triglyceride synthesis by stimulation of lipoprotein lipase = breaks down lipoproteins to FFAs so they can enter adipocytes.
Simulates FA synthesis from glucose.
Inhibits lipolysis in adipocytes.
26
What effects does insulin have on protein and aa metabolism?
Overall: Increased protein synthesis.
MM: stimulates aa uptake
LIVER and MM: increased rate of protein synthesis, inhibits protein catabolism. Inhibition of gluconeogenesis.
27
What are the chronic metabolic effects of insulin?
Changes the expression of many metabolic enzymes:
Increased expression of anabolic enzymes, decreased catabolic enzymes.
28
What are the effects of insulin on cell growth?
Stimulates cell growth and DNA synthesis (mitogen - links to cancer).
29
What type of receptor is the insulin receptor?
Tyrosine Kinase enzyme.
30
What is the precursor to glucagon and where is it made?
Proglucagon (LARGE precursor)
a-cells in pancreas
L-cells in intestine
Processing of proglucagon ends up giving Glucagon (a-cells), GLP-1 and GLP-2 (intestinal)
31
What is the major site of glucagon action?
Liver.
Increases liver glucose release to increase blood glucose levels.
Increased glycogenolysis (Glycogen phosphorylase)
Increase gluconeogenesis (Increase uptake of glycogenic aa's).
32
Discuss regulation of glucagon secretion
STIMULATION:
Neural: PNS (CNX Ach) & SNS (epi/norepi)
Hormonal: GIP, CCK (also stimulates gallbladder contraction and pancreatic enzyme secretion, slows gastric emptying)
Nutrients: Low glucose, aa (ala, arginine)
INHIBITION:
Hormonal: GLP-1, somatostatin, insulin
Nutrients: High glucose.
33
Discuss somatostatin
The major form in islet cells is SS-14, but found in many tissues.
Release from d-cells is stimulated by glucose, sulfonylureas, aa's, CCK, cAMP.
Release from d-cells is inhibited by cholinergic stimulation.
d-cells provide (-) feedback by inhibiting both insulin and glucagon. This ensures islet endocrine output is reset when blood glucose gets back to set point.
Ensures timely reduction of insulin secretion.
34
Discuss IAPP/amylin
Cosecreted with insulin from B-cells.
Slows gastric emptying.
Slows glucagon secretion.
Regulates blood glucose in an INSULIN SPARING fashion.
35
Discuss pancreatic polypeptide (PP)
Secreted postprandially.
Delays gastric emptying.
Reduces acute food intake.
36
Discuss ghrelin
Expressed in islet during development.
Secreted by endocrine cells in gastric fundus.
Stimulates growth hormone from pituitary (GH inhibits insulin action).
Important in appetite regulation, increases appetite.
37
What is the major clearance site for glucagon?
Renal capillary bed.
38
Discuss the role of glucocorticoids (cortisol) in carbohydrate metabolism.
Counter-regulatory to insulin action.
Important for blood glucose during fasting.
Increases liver gluconeogenesis.
39
At what mM levels do the following mechanisms take action:
1. Insulin release
2. Glucagon release
3. Epinephrin release
4. Growth hormone release
5. Cortisol release
1. 4.6
2. 3.8
3. 3.8
4. 3.7
5. 3.2 (dangerous level)
40
What type of dysfunction is central to both T1D and T2D?
Islet dysfunction.
T1D: Beta-cell-specific AUTOIMMUNITY, involves both genes and environmment.
T2D: Diabetogenic environment (obesity/insulin resistance) - B cell stressors
41
What can be used to predict T1D in an individual?
Autoantibodies that are markers of immune response.
42
What type of disease is T1D classified as?
Autoimmune.
Associated with other autoimmune diseases.
Strong genetic association with HLA loci.
Islet cell antibodies (ICAs) to B cell granule proteins (insulin, GAD)
Specific T lymphocyte attack on B cells.
43
Disease concordance for T1D in identical twins
>50% (suggests environmental component is necessary)
Polygenetic.
44
Discuss the environmental component of T1D
Disease SUSCEPTIBILITY is inherited, disease is not.
Environmental triggers:
*Viruses (enteroviruses-coxsackie)
Diet/nutrition (Vit D deficiency)
Stress (B cell stress, insulin resistance)
45
Diabetes Mellitus definition
A chronic incurable disease characterized by elevated blood glucose, resulting from defective insulin production and/or action.
***need B cell dysfunction
46
Discuss the epidemiology of T1D
Most common in children, but also found in adults.
Incidence: 1:400
Increasing at 3%/year
Approximately 300,000 Canadians
47
Therapeutic interventions for T1D
Replace B cells via stem cell or donor islet transplantation.
Replace insulin with pumps.
48
Other potential sources for islet transplant
Human organ donors
Xenotransplant (pigs)
Embryonic stem cells (genetic engineering for better B cells)
48
Immunotherapy in T1D prevention and recent-onset T1D
Has alot of promise:
Peptide antigen therapy (insulin)
Abatacept
Ustekinemab
Golimumab
Teplizumab - $200k/yr, only delays disease by 2 years.
Target different parts of immune pathway.
Carry risk.
Delay but do not prevent.
49
T2D epidemiology
Usually occurs in >45 years but now seen in children.
90% of all diabetes.
6.4% prevalence worldwide
12-14% prevalence US
>90% concordance in identical twins
Frequent in certain ethnic groups.
Associated with sedentary lifestyle and western diet.
50
Progression of T2D
Early:
Impaired glucose tolerance (IGT)
Normal fasting glucose w/abnormal
Treated w/diet and exercise.
Overt but mild:
Moderate fasting hyperglycemia (7mM)
Insulin resistance present
Insufficient insulin secretion
Treated with diet/exercise, oral agents.
Advanced:
Severe fasting hyperglycemia (>9mM)
Insulin secretion greatly impaired or absent
Often requires insulin for treatment.
51
Characteristics of insulin secretion in T2D
Impaired glucose-induced insulin secretion.
Impaired proinsulin processing (hyperproinsulinemia).
Inability to adapt to increasing insulin resistance.
Progressive decline in insulin secretion.
52
Causes of loss of insulin secretion in T2D
1. Glucolipotoxicity: prolonged exposure to high glucose and FFAs is toxic to B cells.
2. Pro-inflammatory cytokines: increased # of islet macrophages making pro-inflammatory cytokines.
3. Islet amyloid deposits: toxic amyloid deposits composed of IAPP/amylin
**Includes both B cell dysfunction and death. B cell exhaustion/stress/failure.
53
Discuss insulin resistance in T2D
Involved genetic and/or acquired post-receptor defects in insulin action.
Associated w/obesity, *Visceral obesity. BMI:insulin resistance.
Can arise with other syndromes (polycystic ovaries) or rare gene mutations.
Associated with inflammation in adipose tissue.
54
What is the best prevention for T2D?
Lifestyle (58% risk reduction).
55
Genes associated with T2D
Most are related to B cell function
HHEX/IDE
Zinc transporter
TCF7L2
PAM
Usually confer risk of disease: disease is POLYGENIC.
56
Monogenic forms of diabetes
MODY Mature Onset Diabetes of the Young
Usually occurs before age 30.
Not associated with obesity.
Familial.
14 different types of genetic mutations.
Neonatal Diabetes Mellitus
Rare.
Sulfonylurea receptor mutation.
Gestational Diabetes Mellitus
Appears during pregnancy and resolves after birth.
Risk for infant: increased size, difficult birth.
>50% later develop T2D.
Pregnancy may unmask genetic impairments in B cell function.
Insulin resistance d/t protective factor that makes sure baby gets the nutrients preferentially.
57
How is diabetes classified?
By the pathogenic process leading to hyperglycemia.
1. T1D
2. T2D
3. GDM
4. MODY
5. Secondary diabetes: medication/drug related, exocrine pancreas related, endocrinopathy (Cushings), infection, other.
58
Etiology of T1D
Autoimmune or non-autoimmune-mediated destruction of B cells.
59
What lab investigations can be used to help diagnose T1D?
C-peptide
anti-GAD Ab
anti-ICA Ab
60
Type 1a vs Type 1b
Type 1a: immune-mediated B cell destruction (95%)
Type 1b: idiopathic B cell destruction (5%)
61
T2D etiology
Insulin resistance due to obesity, abnormal insulin receptors, adipokines, inflammation, B cell defects, and metabolic syndrome.
62
Risk factors for T2D
Genetic!!
Family hx
Ethnicity
Obesity
Diet
Sedentary lifestyle
Smoking
63
What lab investigations can be used to help diagnose T2D?
Cr/eGFR
UACR
Lipid panel
Diabetic eye exam
64
What are the 4 ways BG is monitored?
1. A1c
2. CBG: capillary blood glucose
3. isCGM: intermittently-scanned continuous glucose monitoring
4. trCGM: real-time continous glucose monitoring
65
List the benefits and limitations of the 4 ways of BC monitoring.
66
Discuss a structured educational program to facilitate behaviour change results in patients.
Teach patients:
How and when to perform CBG
How to record the results
Meaning of various BG levels
How behaviour and actions affect BG results
67
Discuss frequency of CBG monitoring with:
Dietary/Lifestyle or Oral medication
Basal insulin once daily
Twice daily insulin
Basal bolus insulin QID or insulin pump
Dietary/Lifestyle or Oral Medication:
Glucose in target - test 1-2 times/week.
Glucose not in target - before and 2 hours after a different meal each day OR 7/day for 1 day/week AND before and after exercise.
Basal insulin 1/day:
Glucose in target - test before breakfast daily.
Glucose not in target - test before breakfast daily and alternate before supper/hs daily.
Twice daily insulin:
Glucose in target - test before breakfast and before supper.
Glucose not in target - test QID acmeals and hs until in target.
Basal bolus insulin QID or insulin pump:
Glucose is stable/in target - test QID acmeals and hs
Glucose not in target - test 7 times/day.
68
What is important to remember about CGM?
Monitors BG in interstitium ea 1-5 minutes.
5-15 minute lag = may not helpful for hypoglycemic events.
BG should be confirmed with CBG before changing treatment.
Alarms can be programmed for highs/lows.
69
What is advantage of an ambulatory glucose profile?
Makes it easier to visualize glycemic patterns by taking 14 days and superimposing them over a 24 hour pattern.
Shows median, quartiles and 10/90th percentiles.
70
What glucose metric is becoming the Gold standard.
Time In Range (TIR)
% of values between 3.9-10.0mM/L
70% TIR equates to approx A1c of 7.0% with each 10% of TIR equating to about 0.5% change in A1c.
71
Glucose Management Indicator (GMI)
Glucose metric that shows approximate A1c based on avg CGM readings for 14+ days.
May differ from measured A1c because it is from 14ish days, not 8-12 weeks.
72
What questions help with interpretation of AGP graphics?
1. Are there patterns of hypoglycemia?
2. Are the readings within the target range?
3. What is the shape of the median curve?
4. What is the degree of variability?
73
What are shown benefits of CGM for those on basal-bolus insulin therapy?
Reduce A1c (~0.5%)
Increase TIR
Reduce hypoglycemic events
Improve QOL and hypoglycemic distress
74
Diabetes Canada guidelines for BG monitoring
A1c ea 3 months
T2D not on insulin: CBG individualized depending on meds, A1c level, and risk of hypoglycemia.
Increased testing at QID and/or overnight when A1c not in target or episodes of hypoglycemia.
T1D w/basal bolus or CSII: rtCGM
T2D w/basal-bolus and not in A1c target: rtCGM or isCGM
75
Discuss the basal/bolus concept of insulin secretion
Bolus: Facilitates glucose uptake after meals.
Basal: Suppresses glucose production between meals and overnight.
76
Discuss insulin pumps
AKA CSII Continuous Subcutaneous Insulin Infusion
Contains rapid acting analogue insulin
Delivers basal rate through the day, rates can be adjusted for different times.
Bolus released prior to meals, adjusted for carb intake and current BG.
Insertion site changed ea 2-3 days.
77
Advantages of insulin pumps
More precise dosing
Multiple basal rates
More reliable insulin absorption
Improved BG control and A1c w/out hypoglycemia
Flexibility in lifestyle
Stabilizes BG
Improved QOL/satisfaction
78
Disadvantages of insulin pumps
Mechanical failure more likely (educate patients on trouble shooting)
DKA may develop more rapidly if pump fails
Skin probs/infections
Expensive
Complex
Psychological factors/body image
Must be supervised by specialist/experienced team.
79
Indications for insulin pumps
Insulin treated diabetes
Need to normalize glucose
Need for flexibility
Hectic lifestyle (shift work/excercise)
Motivated, responsible, and considers safety (carries emergency supply)
80
Discuss establishing basal and bolus pump doses.
Start by calculating 80% of prepump total daily dose.
Of this amount 50% is basal and 50% is allocated to bolus.
Divide basal by 24 hours for hourly basal dose.
Calculate average daily carb intake and divide by total bolus amount (eg 1:10 means 1 unit insulin for ea 10 g carbs) OR 500/TDI = carb ratio
81
Discuss Insulin Sensitivity or Correction Factor
How much do we think 1 unit of insulin will lower BG.
100/TDD of insulin.
eg TDD = 40 U
100/40 = 2.5; 1 unit of insulin will lower BG by 2.5 mM/L
82
Closed-Loop syher stems
CGM connected to pump
Allows for automated insulin delivery (AID).
Still need to tell the pump when and how much you are eating.
Improve A1c and TIR more than other systems.
Free downloadable software algorithms available:
Loop, iAPS, AndroidAPS
83
Smart insulin pens
Reusable insulin pen that connects via bluetooth.
Records and tracks doses.
Helps calculate dose for a meal.
84
Online resources for insulin dosing.
Boluscalc.
mySugr
MyFitnessPal
CalorieKing
85
What is the main risk factor for complications in chronic DM?
Hyperglycemia.
Genetics, BP, lipids, and epigenetic factors also important.
86
Which cells are most predisposed to hyperglycemic change?
Retina
Glomerular mesangial cells
Schwann cells
They are less able to deal with intracellular hyperglycemia.
87
What are the 3 classic types of microvascular complications of chronic DM?
1. Diabetic nephropathy
2. Diabetic retinopathy
3. Diabetic neuropathy
88
What is the #1 cause of end-stage renal disease (ESRD) (aka kidney failure) worldwide?
Diabetic nephropathy.
Often correlates with diabetic retinopathy.
89
Discuss the pathophysiology of diabetic nephropathy.
Podocyte loss through detachment and apoptosis leads to hypertrophy, reduction in slit diaphragms, and basement membrane thickening.
Albumin leaks out of blood into glomerulus, leading to glomerluar HTN.
Increased pressure forces larger molecules into urine.
Tubular cells have to work harder leading to hypertrophy, scarring, and decreased reabsorption capacity.
Mesangial cells undergo hypertrophy and proliferation.
90
What is used to assess diabetic nephropathy?
GFR (eGFR from creatinine measurement)
Albumin in the urine (Urine ACR will be high in diabetic nephropathy)
91
What are the stages of diabetic nephropathy?
1. Hyperfiltration, increased GFR
2. Silent, normal GFR
3. Microalbuminuria - usually the first clinically apparent sign
4. Macroalbuminuria - overt nephropathy, larger amounts of albumin in urine
5. ESRD (Ends stage renal disease)
**Not all patients have this typical progression
**Not all patients have albuminuria
92
Discuss screening for nephropathy in DM
Creatinine & eGFT at least 1/year and increased frequency if abnormal.
Spot urine ACR 1/year (lots of false positives from infection, dehydration)
Start screening at most 5 years after Dx of T1D
Start screening at Dx of T2D
93
Discuss management of diabetic nephropathy
Overarching: Control BG, HTN, lipids
Secondary prevention in order:
1. ACE inhibitor or ARB
2. SGLT2 inhibitor
3. MRA (finerenone)
4. GLP1 agonist
94
What is the leading cause of blindness in developed countries and what ethnic profiles are most affected?
Diabetic retinopathy
White then Hispanic then Black.
95
What 2 processes are associated with diabetic eye disease?
1. Diabetic retinopathy; non-proliferative, proliferative
2. Diabetic macular edema
Can be 2 separate processes.
96
Discuss the pathophysiology of diabetic eye disease.
High BG leads to pericyte loss, basement membrane thickening, retinal blood flow change.
This leads to microaneurysm formation which leads to vascular leakage (MAKULAR EDEMA w/moderate visual loss).
Microaneurysms progress to retinal hemorrhages (w/moderate visual loss)
MILD NON-PROLIFERATIVE DIABETIC RETINOPATHY
Eventually see increased vascular endothelial growth factors which leads to vascular leakage (MAKULAR EDEMA) and neovascularization
PROLIFERATIVE DIABETIC RETINOPATHY
97
Diagnosis of retinopathy
1. Fundoscopy: microaneurysms, exudates, cotton wool spots, neovascularization
2. Optical Coherence Tomography for macular edema
3. Fluorescein Angiography to evaluate blood flow and leakage (rarely done)
98
Screening of retinopathy
Dilated retinal exam annually.
Start at MOST 5 years post Dx of T1D
Start at Dx of T2D
99
Management of diabetic retinopathy
1. Anti-VEGF antibodies (intravitreal injections):
Can be used for macular edema or severe/proliferative retinopathy.
Ranibizumab, Bevacizumab, Aflibercept
2. Photocoagulation (laser):
Pantretinal for severe/proliferative retinopathy.
Focal for edema
3. Vitrectomy (removal of vitreous humour) rare:
Used for non-clearing vitreous hemorrhage, persistent neovascularization, vitreoretinal traction
100
What are the challenges in diagnosing diabetic neuropathy?
Vastly underdiagnosed in clinical practice bc the tools used for diagnosis are not perfect and a full neuro exam is time consuming.
101
List the types of diabetic neuropathy
1. Distal symmetric polyneuropathy (stocking-glove distribution, 40-80% of DN)
2. Radiculopathy plexopathy (nerve root or plexus distributions, <5% of DN)
3. Mononeuropathy (single nerve distribution, 5-30% of DN)
4. Autonomic neuropathy **Most worrisome (Heart, Stomach, Intestines, Bladder, 5-15% of DN)
102
Discuss screening for diabetic neuropathy
HISTORY
(+) sx: paresthesia, burning, lancinating, allodynia
(-) sx: loss of pain, temp, vibration, proprio
CLINICAL EXAMINATION
Detail foot exam annually
10g monofilament testing
128 Hz tuning fork
Strength, reflexes
103
Management of diabetic neuropathy
Gabapentinoids (gabapentin, pregabalin)
SNRI antidepressants (duloxetine, venlafaxine)
Tricyclic antidepressants (amitriptyline, nortritypline)
Improvement of 30-50% with single agent. Can use combos but risk of side effects.
104
What are the macrovascular complications of DM?
1. CV disease
2. Cerebrovascular disease
3. Peripheral vascular disease (claudication, arterial ulcer, acute limb ischemia)
104
Multifactorial complications of DM
1. Diabetic foot infections and ulcers
2. Sexual dysfunction
105
Diabetes Control & Complications Trial (DCCT)
Intensive control vs conventional therapy over 9 years
A1c w/intensive reduced (7.2 vs 9.1 in conventional)
Nephropathy reduction
Retinopathy reduction
Macrovascular complication reduction
106
Epidemiology of Diabetes Interventions & Complications (EDIC) study
Followed sample populations from DCCT for 20+ years after intervention (still ongoing)
A1c from both groups averages around 8%
Reduction in macrovascular complications = METABOLIC MEMORY
107
UK Prospective Diabetes Study (UKPDS)
Intensive vs conventional in newly diagnosed T2D
Original cohort followed for 10 years with longer updates (current)
Intensive:
Decrease CV complications
108
Prevention of complications in DM (acronym)
A: A1c
109
How often should DM screening tests be done?
110
What are the main methods of T2D prevention?
Lifestyle modifications
Pharmacologic agents
Surgical interventions
111
Diagnostic criteria for diabetes
Fasting glucose >= 7
2hour glucose on OGTT >=11.1
Random glucose >= 11.1
A1c >=6.5
112
Diagnostic criteria for prediabetes
Fasting glucose 6.1-6.9
2-hour glucose on OGTT 7.8-11
A1c 6-6.4
113
Recommendations for those w/prediabetes
Moderate weight loss
150 min/week over 5 days of physical activity
May consider metformin
114
Recommendations for those at risk of T2D
Mediterranean diet
DASH diet
exercise
weight loss
115
What are the names of the most important studies regarding diet and exercise and diabetes risk?
Da Qing
DPS
DPP
116
What do studies show regarding diet and exercise vs risk of T2D?
Overall 32% reduction in risk.
117
Discuss DPP
Diabetes Prevention Program
Basis of international risk management recommendations.
Standard lifestyle vs intensive lifestyle vs metformin
Intensive lifestyle decreased risk 58%, 27% at follow up.
Metformin decreased risk 31%, 18% at follow up.
118
Principles of nutrition therapy in managing T2D risk
Must be individualized and involve a dietician.
No specific macros are ideal.
Reduce overall carb consumption.
Low GI carbs.
Strongest evidence for low-carb & Mediterranean diets.
119
What medications are used for risk management against T2D?
Metformin
GLP1 agonists
SGLT2 inhibitors
120
What surgical interventions are used for risk management against T2D?
Bariatric surgery for those with BMI >=35 when healthy interventions are inadequate
121
Exercise fuel paradox
Protect muscle glycogen but also protect blood glucose.
122
Insulin's effect on the liver
Promotes glycogen synthesis/inhibits glycogenolysis.
Promotes glycolysis/inhibits gluconeogenesis.
Promotes lipid synthesis and storage.
Promotes protein synthesis.
123
Insulin's effect on muscle
Promotes glucose uptake.
Promotes glycogen synthesis (glycogenesis)
Promotes protein synthesis.
124
Insulin's effect on adipose tissue
Promotes glucose uptake.
Promotes lipid synthesis and storage.
125
Exercise effects on the liver and glucose
Promotes glycolysis (breakdown of glucose)
126
Exercise effects on muscle and glucose
Promotes glucose uptake
127
Epinephrine effects on liver
Promotes glycogenolysis
Promotes gluconeogenesis
128
Epinephrine effects on muscle
Promotes glucose uptake.
Promotes glycogenolysis.
Promotes glycolysis.
129
Epinephrine effects on adipose tissue
Promotes lipolysis
130
Epinephrine effects on the pancreas
Inhibits insulin secretion.
Promote glucagon secretion.
131
Glucagon effects on the liver.
Promotes glycogenolysis.
Promotes gluconeogenesis.
Inhibits glycogen synthesis.
132
Glucagon effects on adipose tissue.
Promotes lipolysis.
133
Discuss molecular signalling in contraction-induced GLUT4 translocation.
Contraction causes NO to act within the cell:
Contraction causes ATP to AMP to AMPK pathway:
Contraction causes Ca release:
All result in bringing the GLUT4 storage vesicle to the cell membrane.
Can induce a 100x increase in glucose uptake (intensity and duration dependent)
134
How long can the effects of exercise last on GLUT4 receptors?
Up to 72 hours.
135
How does muscle act as an endocrine organ?
Contraction causes production of MYOKINES (IL6)
IL6 activates:
Muscle - increased glucose uptake and fat oxidation
Liver - increase glucose production
Adipose - increased lipolysis
Blood vessels - growth/proliferation
136
What are the factors that influence muscle glucose uptake during exercise?
Supply - perfusion/BG concentration
Transport - GLUT abundance, glucose gradient
Metabolism - Hexokinase activity, substrate flux
Myokine IL6 - Increased mm temp and mechanical effects.
137
What types of factors show the impact of activity on T2D?
Incidence of T2D/expression of risk
BG levels
GLUT4 volume and activity
A1c values
138
What were the findings of the Finnish Diabetes Prevention study?
A few years of lifestyle focussed prevention gives long-term protection.
Postpones T2D in those with high risk by years.
Legacy effect on BG control.
139
2 weeks of HIT training had what effect on GLUT4 transporters?
370% increase.
140
What type of activity showed an absolute decrease of .9 in A1c
Combined resistance and aerobic.
141
Exercise prescription for T2D
Frequency: 24 hr guidelines: aerobic and resistance, no more than 2 days without exercise.
Intensity: moderate-vigorous
Type: combination
Timing: AM/PM, pre/post prandial.
142
What are the 3 characteristics of DKA (aka DKA triad)?
Hyperglycemia
Presence of ketones
Acidosis
143
Epidemiology of DKA
T1D: 66%
T2D: 33%
4.6-8 per 1000 person years.
5000-10000 hospitalizations
.2-2.5% mortality with recurrent DKA 30%
144
DKA clinical features
Prodrome (1-2days)
Volume depletion
Kussmaul breathing
Acetone breath
Myalgia
Normal temp/hypothermia
Abdominal pain
145
Precipitating conditions for DKA
Acute illness
New onset diabetes
Insulin under-dosing
Meds; corticosteroids, anti-psychotics, anticonvulsants, SGLT2 inhibitors, immune checkpoint inhibitors.
Drugs
146
Mechanism of DKA
Absolute insulin deficiency.
Loss of suppression of glucagon leading to gluconeogenesis and FFAs.
B oxidation leads to acetoacetate production.
Acetoacetate in equilibrium w/B hydroxybutyrate and acetone.
147
Discuss serum K in DKA
Can be high or low.
However, DKA is a K depleted state so need to monitor serum K hourly because they will need it at some point.
148
Mechanisms of hypokalemia in DKA
Osmotic diuresis (mass effect) and Hyperaldosteronism lead to kaliuresis.
Anorexia
Loss d/t vomiting or diarrhea.
149
Mechanisms of hyperkalemia in DKA
Shift of K from intra to extra cellular space (insulin deficiency and acidosis)
Decrease K excretion in kidney d/t volume depletion.
150
Normal anion Gap vs Wide or High anion gap
Normal 10-14
High >16
151
MUDPILES
Methanol
Uremia
DKA
Propylene glycol
Iron/Isoniazid
Lactic acidosis
Ethanol/ethylene glycol
Salicylates/ASA/Aspirin
152
GOLDMARK
Glycols (ethylene & propylene)
Oxoproline
L-lactate
D-lactate
Methanol
Aspiring
Renal failure
Ketoacidosis
153
Management of DKA
1. Volume repletion - NS 4-6L, 1/2NS if Na elevated
2. Insulin infusion - 6-10 unit bolus, then .1 units/kg/hr except is K is >3.3
3. K repletion
4. Reduce plasma glucose
5. Treat precipitating condition
6. Avoid complications - hypokalemia, CE
***MONITOR
154
Discuss Cerebral Edema
Occurs in children usually within 4-24 hours after initiation of tx for DKA.
Occurs in 1.5% of cases.
Mortality rate as high as 24%.
D/t a combination of factors: secondary to acidosis, damage to cerebral vascular endothelium which increases blood brain barrier premeability.
155
S&S of Cerebral Edema in pediatric DKA
Mental status - somnolence, irritability
Focal neurologic deficits
Age-inappropriate incontinence
Headache
***Cushings triad - HTN, brady cardia, irregular respiration
Hypoxemia - compression of respiratory center
156
Management of CE
EMERGENCY - NEVER WAIT TO CONFIRM
Elevate head of bed
Reduce fluid IV 33%
Mannitol, repeat if no clinical response in 30-120 minutes
3% hypertonic saline
May require intubation/mech vent to manage respiratory depression
157
Define Hyperglycemic Hyperosmolar State
Metabolic decompensation (usually T2D) resulting from relative insulin deficiency, severe hyperglycemia, leading to hyperosmolality and volume depletion.
158
What are the 3 characteristics of HHS
SEVERE hyperglycemia
Hyperosmolality
SEVERE volume depletion
159
HHS clinical features
Age - often >60
Prodome - early polydipsia/polyuria, late weakness, confusion, lethargy, decreased urine output.
TAKES WEEKS TO DEVELOP
Poor fluid intake, glucose containing fluid when they do.
Volume depletion
Lethargy, stupor, coma
Hypothermia d/t decreased peripheral perfusion.
160
HHS precipitating conditions
Acute illness
Druges - CCBs, phenytoin, thiazides, steroids
161
HHS clinical presentation
Volume depletion
Neurological - lethargy, coma, hemianopsia, hemiparesis, seizures.
BG>33.3
162
How does the pathophysiology differ in HHS vs DKA
DKA has an increase in counter-regulatory hormones d/t lack of insulin.
HHA has no increase in counter-regulatory hormones bc there is only a relative insulin deficiency. This means not as many ketone bodies produced.
163
Calculating plasma osmolality
2x[Na] + [glucose] + [urea]
normal 285-295
HHS >320
164
HHS management
1. Volume repletion - 1/2NS 5-10L
2. Normalize glucose
3. K repletion
4. Treat precipitating condition
5. MONITOR
165
Counselling a patient upon discharge after DKA/HHS
Must be eating and drinking well.
Glucose controlled w SC insulin
Precipitating condition must be treated.
Instructions:
Increase insulin w/ illness
Increase fluid intake w/ illness
Monitor BG frequently
Treat infections early
Contact MD if no improvement within 24 hours.
166
Clinical features of hypoglycemia
Autonomic (epi/norepi) - perspiration, tachycardia, tremor, hunger, anxiety, increased tem, nausea.
Neuroglycopenic - Dizzy, weak, blurred vision, drowsy, confusion, seizure/coma
167
Pathophysiology of hypoglycemia in T1D
Increased exogenous insulin leads to
Decreased BG
BUT no glucagon/epinephrine (loss of ability to counter regulate can occur 10-15 years after diagnosis)
Reduced or absent hepatic glucose output means no increase in BG.
168
Risk factors for hypoglycemia
Age
Cognitive dysfunction
Liver/kidney dysfunction
Adrenal insufficiency
Lack of diabetes education
Alcohol consumption
Exercise
Food insecurity
Missed/late meals
Meds
Long standing diabetes
169
Progressive loss of hypoglycemic symptoms
The more you have hypoglycemic events, the less you experience the adrenergic symptoms and have to rely on the neuro symptoms.
170
Prevention of hypoglycemia
Identify high risk patients and re-evaluate glycemic goals.
Frequent self-monitoring.
Teach support network to identify subtle symptoms.
Use multiple small insulin doses.
Frequent meals/snacks.
171
Treatment of hypoglycemia
Home glucagon injection kits.
Strict hypoglycemic avoidance so that the symptoms can be recognized.
Rapid-acting glucose, repeat if no change in 10-15 mintues.
172
Goals of treatment for diabetes
Reduce risk of macrovascular complications
Reduce risk of microvascular complications
Reduce risks associated with high A1c
173
Why do we focus on A1c for diabetes management?
It is a validated measure of glycemic status.
174
A1c target management
Should be individualized based on:
Risk of complications
Risks of severe hypoglycemia and hypoglycemia unawareness
Age
Functional status
Life expectancy
175
A1c treatment targets if low risk for hypoglycemia but high risk for microvascular complications.
>=6.5
176
A1c treatment targets for most adults w/T1D or T2D
>=7
177
A1c treatment targets for those with recurrent severe hypoglycemia or hypoglycemia unawareness, frail/elderly, dementia, limited life expectancy.
7.1-8.5
178
9 classes of diabetes medications
1. Biguanides
2. Sulfonylureas
3. SGLT2 inhibitors
4. GLP-1 agonists
5. DPP4 inhibitors
6. Thizolidinediones
7. Alpha-glucosidase inhibitors
8. Meglitinides
9. insulins
179
Biguanide mechanism of action and give example of common medication.
Increases insulin mediated glucose uptake
Increases anaerobic glucose metabolism
Decreases gluconeogenesis
Decreases glycogenolysis
Decreases FA oxidation
Metformin
180
Advantages of biguanides
Effective A1c lowering
No significant hypoglycemia
No associated weight gain
181
Disadvantages of biguanides
GI side effects; pain, nausea, diarrhea
Metallic taste
Lactic acidosis (rare)
DN use if eGFR <30
182
Sulfonylurea mechanism of action and give an example of common medication(s)
Close the ATP K channels in B cells. This depolarizes the cell and causes Ca mediated insulin release, independent of glucose.
Glyburide, Gliclazide
183
Advantages of sulfonylureas
Effective A1c lowering
Inexpensive
Easy to administer
184
Disadvantages if sulfonylureas
Risk of hypoglycemia
Weight gain
Unknown effects on the B cell over time.
DN use if eGFR <30
185
SGLT2 inhibitor mechanism of action and give an example of common medication(s)
Blocks SGLT2 channels in the kidney, reducing glucose re-uptake and causing glucosuria
Canagliflozin, Dapagliflozin, Empagliflozin
186
SGLT2 inhibitor advantages
Effective A1c lowering
Easy to administer
Promotes weight loss
Lower BP
Low risk of hypoglycemia
Cardio and renoprotective.
187
SGLT2 inhibitor disadvantages
Polyuria
Volume depletion
UTI
Euglycemic DKA (rare)
Cana may increase amputation/fracture risk
DN use if eGFR <20
188
GLP1 agonist mechanism of action and give example of common medication(s)
Increases endogenous insulin production and secretion
Increases somatostatin
Decreases glucagon secretion
Decreases appetite
Slows gastric emptying
Slows gall bladder secretions
Decreases blood pressure
Liraglutide, Dulaglutide, Semaglutide (Ozempic), Rybelsus
189
GLP1 agonist advantages
Effective A1c lowering
Cardioprotective
Renoprotective
Significant weight loss
190
GLP1 agonist disadvantages
Injections required
Nausea, vomiting, pancreatitis
Expensive
191
DPP4 inhibitor mechanism of action and example of common medication(s)
Inhibits DPP4 which usually breaks down GLP-1
Linagliptin, Saxagliptin, Sitagliptin
192
DPP4 advantages
Easy to administer
Linagliptin can be used even w/low eGFR/renal failure
193
DPP4 disadvantages
Less effective A1c lowering
Pancreatitis, pemphigoid
Cost
194
Thiazolidinediones mechanism of action and example of common medication
PPARgamma activator, increases transcription of genes involved in glucose and lipid metabolism.
Leads to decreased gluconeogenesis and fat content.
Increased glucose uptake in skmm
Increased glucose uptake in adipose, increase lipogenesis, increased FA uptake.
Pioglitazone
195
Thiazolidinediones advantages
Effective A1c lowering
Easy to administer
Durable effect
196
Thiazolidinediones disadvantages
Weight gain, edema
Worsening heart failure
Distal bone fractures
Bladder cancer
Expensive/not covered
197
Alpha glucosidase inhibitor mechanism of action and name of common medication
Inhibits intestinal amylases and glucosidases.
Delays/decreases glucose absorption in the GI tract.
Arcarbose
198
Alpha glucosidase inhibitor advantages
Not systematically absorbed
Targets post-prandial hyperglycemia
199
Alpha glucosidase inhibitor disadvantages
Less effect A1c lowering
Bloating, GI pain, diarrhea, flatulence
Multiple daily dosing
Expensive
DN use if eGFR <30
200
Meglitinides mechanism of action and name of common medication
Closes ATP K channels in B cells, depolarizing cell, leading to insulin release.
Dependent on glucose levels.
Repaglinide
201
Meglitinide advantages
Effective A1c lowering
May be used if meals are irregular
202
Meglitinide disadvantages
Hypoglycemia
Weight gain
Multiple daily dosing
Expensive
203
Short-acting Insulins
Regular
Lispro
Aspart
Glulisine
204
Long-acting insulins
NPH
Glargine
Detemir
Degludec
205
Advance therapy for treatment of A1c or hyperglycemia
Add or substitute GLP1, SGLT2, or insulin
206
Guidelines for treatment of diabetes
Goal - attain A1c target by 3 months
Lifestyle changes/no pharm
Metformin
Insulin +/- metformin if symptomatic or metabolic decomp.
If A1c not at target at 3 months
Start metformin
Adjust or advance therapy
Reassess A1c ea 3 months
207
Advance therapy for treatment of ASCVD, CKD or HF age >60
Add or substitute GLP1 or SGLT2
208
Discuss initiating insulin treatment
Fasting glucose or A1c not on target or metabolic decomp.
Start basal insulin and titrate to get to fasting glucose target.
Continue metformin.
Review/add/adjust other AHAs
Add bolus insulin.
